(Denver, CO — January 18, 2024) - The IASLC is excited to officially launch the 2024-2029 strategic plan. IASLC CEO Karen Kelly, MD, unveiled the society’s five-year strategic plan at WCLC 23, redefining the IASLC’s mission and vision and setting forth an aggressive blueprint to achieve its goals. The plan was developed over several months and is based on input from the IASLC member survey, IASLC’s committees, industry partners, Board of Directors, and staff.
The IASLC’s new strategic plan begins with a reworked mission statement, which is to “be the multidisciplinary world authority on lung and other thoracic cancers through collaborative science, education, and advocacy in order to ensure optimal prevention and patient care.” The plan also incorporates a time element into the society’s vision statement: “Conquering Lung and Other Thoracic Cancers Worldwide in the 21st Century.”
“Adding a time element into our vision statement is not only vital for ensuring accountability, but it also serves as a source of motivation and inspiration.” Dr. Kelly said.
Taken together, the pillars, outcomes, aims, and enablers are designed to serve as a roadmap that guides the organization toward a future characterized by groundbreaking discoveries, compassionate care, and transformative impact.
"Our plan is bold and we're off to a strong start," added Dr. Kelly. Though just launched, the IASLC has already executed new projects in each pillar: the first team science grant award in Pillar 1 (the application deadline is March 4); an expansion of the IASLC Academy, representing the most globally diverse Academy class in its history in Pillar 2; and in Pillar 3, new biomarker survey that will be released for membership input as biomarker identification is the first step in providing optimal patient care.
"To implement our mission and strategic plan, we need all our members to contribute, and I am really looking forward to collaborating as we move further on this track and keep IASLC the leading organization in thoracic oncology," said current IASLC President Dr. Paul Van Schil, Professor of Thoracic and Vascular Surgery, Antwerp University Faculty of Medicine.
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. IASLC also publishes JTO Clinical Research Reports, an open-access publication. Visit www.iaslc.org for more information.